This week’s biotechnology news headlines include, mergers and acquisitions will continue, Teva offers to buy Mylan, Gene Therapy company Dimension receives round of funding, FDA approves generic version of MS drug Copaxone, GSK recalls 1.7 million flu vaccines, MaxCyte and Johns Hopkins collaborate to advance CAR T-Cell therapies, and Cantrixil gets orphan drug designation.
Time:15:00 GMT (Greenwich Mean Time)16:00 CET (Central European Time) 10:00 EST (Eastern Standard Time) 07:00 PST (Pacific Standard Time)
Conferences:
April
International Society for Extracellular Vesicles – April 23-26, 2015 –Washington DC – http://www.isevmeeting.org/Attending? Don’t miss:
“From basic research to clinical setting: Adapting methods for EV culturing, enrichment and analysis”
The aim of this presentation is to provide information on how to optimize experimental conditions for studying cell culture exosomes by a) introducing a Gibco® Exosome-Depleted FBS and b) giving an overview over a direct method for fast, efficient, and selective isolation of exosomes from cell culture supernatant that is compatible with a wide range of downstream applications.
Thermo Fisher Scientific at Booth #19/20
Showcasing their new exosome product, Gibco Exosome-Depleted FBS. They will also be have giveaways inlcuding the Gibco Life of Cells Lego Lab.
Cord Blood World Europe Congress 2015 – May 20-21, 2015 – Business Design Centre, London, UK Build deposits, reduce costs, retain quality, decrease volume and increase utilization.
“Drugmakers will sustain a boom in mergers and acquisitions for some time to come as investors view their dealmaking more positively, according to Adam S. Parker, chief U.S. equity strategist at Morgan Stanley.”
If you like this story, please see our blog titled “2014 FDA New Drug Approvals – 11 Biologics Receive Approval”
“The race is on to be the first to market with a Gene Therapy for hemophilia. And one of the entrants just got a big round of funding in what looks like a prelude to an initial public offering.”
If you like this story, please see our blog titled “A New Model for Continuous Processing in Downstream Purification”
“The U.S. Food and Drug Administration approved on Thursday the first generic version of Teva Pharmaceutical Industries Ltd’s top-selling multiple sclerosis drug, Copaxone.”
If you like this story, please see our blog titled “Materials and Assay Systems Used for 3D Cell Culture”
“MaxCyte® Inc., the pioneer in cell therapies using scalable, high-performance cell transfection systems, today announces a strategic research collaboration with Johns Hopkins University (JHU) to develop unique Chimeric Antigen Receptor (CAR) T-cell therapies, which harness patients’ own immune systems to combat cancers.”
If you like this story, please see our blog titled “Closed Systems in Biomanufacturing Offer A Variety of Benefits”
